MX2020007625A - Inhibidor mtor, composicion farmaceutica y su uso. - Google Patents

Inhibidor mtor, composicion farmaceutica y su uso.

Info

Publication number
MX2020007625A
MX2020007625A MX2020007625A MX2020007625A MX2020007625A MX 2020007625 A MX2020007625 A MX 2020007625A MX 2020007625 A MX2020007625 A MX 2020007625A MX 2020007625 A MX2020007625 A MX 2020007625A MX 2020007625 A MX2020007625 A MX 2020007625A
Authority
MX
Mexico
Prior art keywords
isovalerylspiramycin
pharmaceutical composition
mtor inhibitor
mtor
diseases associated
Prior art date
Application number
MX2020007625A
Other languages
English (en)
Inventor
Xiaofeng Zhao
Mingyu Xia
Xunlei Jiang
Xundong Jiang
Original Assignee
Shenyang Fuyang Pharmaceutical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Fuyang Pharmaceutical Tech Co Ltd filed Critical Shenyang Fuyang Pharmaceutical Tech Co Ltd
Publication of MX2020007625A publication Critical patent/MX2020007625A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Se describe un inhibidor de mTOR, una composición farmacéutica y el uso de los mismos. El inhibidor de mTOR incluye carrimicina, isovalerilespiramicina I, isovalerilespiramicina II e isovalerilespiramicina III, o una combinación de dos o tres de isovalerilespiramicina I, isovalerilespiramicina II e isovalerilespiramicina III. La composición farmacéutica también incluye un fármaco para tratar y/o prevenir enfermedades relacionadas con la vía de mTOR como segundo ingrediente activo. El inhibidor de mTOR tiene un efecto inhibidor obvio sobre las células de enfermedades relacionadas con la vía de mTOR y se usa para preparar fármacos para tratar y/o prevenir enfermedades relacionadas con la vía de mTOR.
MX2020007625A 2018-01-19 2019-01-18 Inhibidor mtor, composicion farmaceutica y su uso. MX2020007625A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810052779 2018-01-19
PCT/CN2019/072411 WO2019141254A1 (zh) 2018-01-19 2019-01-18 一种mTOR抑制剂、药物组合物及其应用

Publications (1)

Publication Number Publication Date
MX2020007625A true MX2020007625A (es) 2020-11-24

Family

ID=67300871

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007625A MX2020007625A (es) 2018-01-19 2019-01-18 Inhibidor mtor, composicion farmaceutica y su uso.

Country Status (10)

Country Link
US (1) US20200405739A1 (es)
EP (1) EP3741374A4 (es)
JP (1) JP7127136B2 (es)
KR (1) KR20200112897A (es)
CN (1) CN110051845A (es)
AU (1) AU2019209738A1 (es)
CA (1) CA3088818A1 (es)
MX (1) MX2020007625A (es)
RU (1) RU2768583C2 (es)
WO (1) WO2019141254A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200112897A (ko) * 2018-01-19 2020-10-05 쉔양 푸양 파마슈티컬 테크놀로지 컴퍼니 리미티드 mTOR 억제제, 약물 조성물 및 이의 응용
MX2020007627A (es) 2018-01-19 2020-11-24 Shenyang Fuyang Pharmaceutical Tech Co Ltd Uso de la carrimicina o de sus ingredientes activos.
US20220211735A1 (en) * 2019-05-16 2022-07-07 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Medicament and combination product used for preventing, alleviating and/or treating fibrosis, and use thereof
CN111264469B (zh) * 2020-02-27 2022-03-25 西安交通大学医学院第一附属医院 一种基因免疫诱导的甲状腺相关性眼病动物模型的构建方法及雷帕霉素类药物的应用
US11351185B2 (en) 2020-03-11 2022-06-07 Asclea Corporation Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis
CN113577086B (zh) * 2020-04-30 2023-05-02 沈阳福洋医药科技有限公司 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用
WO2021219112A1 (zh) * 2020-04-30 2021-11-04 沈阳福洋医药科技有限公司 异戊酰螺旋霉素类化合物或其组合物在制备治疗脓毒症疾病药物中的应用
CN112294967A (zh) * 2020-09-30 2021-02-02 四川大学 一种mTOR抑制剂与抗癌药物的用途
CN113018441B (zh) * 2021-02-26 2023-12-19 中国科学院深圳先进技术研究院 一种基于宏量营养素成分改变和mTOR信号抑制剂的饥饿干预方法和应用
CN113750097A (zh) * 2021-10-11 2021-12-07 上海市第十人民医院 Hayatine及其类似物在制备mTORC1抑制剂中的应用
CN114246949B (zh) * 2021-12-14 2023-02-17 上海交通大学医学院附属第九人民医院 Ulk1激活剂在预防和/治疗听力损伤中的应用
CN114621338B (zh) * 2022-03-11 2022-11-11 中山大学 一种mTOR抑制剂及其应用
CN115737819A (zh) * 2022-09-28 2023-03-07 众爱数字医疗科技(广东)有限公司 药物组合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1237976C (zh) * 2003-12-23 2006-01-25 沈阳同联集团有限公司 必特螺旋霉素及其在抗感染性疾病中的应用
US9486467B2 (en) * 2006-06-12 2016-11-08 Ramot At Tel-Aviv University Ltd. Method of treating colorectal cancer that expresses a mutated APC gene by administering erythromycin or tylosin
CN101785779B (zh) * 2010-03-09 2014-03-05 沈阳同联集团有限公司 异戊酰螺旋霉素ii的分离制备
WO2011110084A1 (zh) * 2010-03-09 2011-09-15 沈阳同联集团有限公司 异戊酰螺旋霉素ⅰ、ⅱ或ⅲ的分离制备方法、及含有它们的药用组合物及其应用
CN101785778A (zh) * 2010-03-09 2010-07-28 沈阳同联集团有限公司 异戊酰螺旋霉素i的分离制备及其应用
DK2578596T3 (en) * 2010-05-25 2017-07-17 Shenyang Fuyang Pharmaceutical Tech Co Ltd LEVOCARRIMYCIN, PHARMACEUTICAL COMPOSITIONS, METHODS OF PRODUCTION AND APPLICATIONS THEREOF
PL3210991T3 (pl) * 2010-05-25 2020-03-31 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Postać krystaliczna lewoizowalerylospiramycyny II oraz preparaty, sposoby wytwarzania i ich zastosowanie
JP7060631B2 (ja) * 2017-07-04 2022-04-26 沈陽福洋医薬科技有限公司 腫瘍を治療および／または予防する薬物の調製におけるイソバレリルスピラマイシンｉ、ｉｉおよび／またはｉｉｉの応用、ならびに薬物
KR20200112897A (ko) * 2018-01-19 2020-10-05 쉔양 푸양 파마슈티컬 테크놀로지 컴퍼니 리미티드 mTOR 억제제, 약물 조성물 및 이의 응용
MX2020007627A (es) * 2018-01-19 2020-11-24 Shenyang Fuyang Pharmaceutical Tech Co Ltd Uso de la carrimicina o de sus ingredientes activos.

Also Published As

Publication number Publication date
EP3741374A1 (en) 2020-11-25
US20200405739A1 (en) 2020-12-31
WO2019141254A1 (zh) 2019-07-25
JP7127136B2 (ja) 2022-08-29
JP2021516663A (ja) 2021-07-08
RU2020126432A (ru) 2022-02-21
RU2768583C2 (ru) 2022-03-24
CN110051845A (zh) 2019-07-26
AU2019209738A1 (en) 2020-09-10
KR20200112897A (ko) 2020-10-05
CA3088818A1 (en) 2019-07-25
RU2020126432A3 (es) 2022-02-21
EP3741374A4 (en) 2021-04-07

Similar Documents

Publication Publication Date Title
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
BR112018073663A2 (pt) moduladores de receptores nmda spiro-lactâmicos e seus usos
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
BR112015018087A8 (pt) composto, composição farmacêutica e uso
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
BR112016001544A8 (pt) composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
WO2019014322A8 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
MX2020010938A (es) Medicamento para prevenir y/o tratar el dolor y/o la fiebre, producto compuesto y uso del mismo.
MX2020007627A (es) Uso de la carrimicina o de sus ingredientes activos.